A5020235177- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Head and Neck Cancer Studies
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Galectins and Cancer Biology
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- vaccines and immunoinformatics approaches
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Lymphoma Diagnosis and Treatment
- T-cell and B-cell Immunology
- Bladder and Urothelial Cancer Treatments
- COVID-19 and healthcare impacts
- Neuroendocrine Tumor Research Advances
- Sarcoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- Radiopharmaceutical Chemistry and Applications
University Hospital of Geneva
2015-2024
Hôpital Beau-Séjour
2011-2024
University of Geneva
2014-2024
Geneva College
2021-2024
University of California, San Francisco
2024
Swiss Cancer Center Léman
2021-2024
Kantonsspital St. Gallen
2005-2023
Witten/Herdecke University
2020-2022
Gemeinschaftskrankenhaus Herdecke
2022
University Hospital of Bern
2005
For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% the SAKK 16/00 trial is an accepted standard care. We investigated additional benefit perioperative treatment durvalumab.Neoadjuvant consisted three cycles 100 mg/m2 85 once every 3 weeks two doses durvalumab 750 mg 2 weeks. Durvalumab was continued for 1 year after surgery. The primary end...
Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell immunoglobulin domain mucin domain-3 (TIM-3) programmed death-1 (PD-1), respectively. This phase I/II study evaluated the safety efficacy of sabatolimab, with or without spartalizumab, in patients advanced solid tumors. Patients Methods: Primary objectives I/Ib part were to characterize estimate recommended II dose (RP2D) for future studies. Dose escalation was guided by a Bayesian (hierarchical) logistic...
Small intestine plasmacytoid dendritic cells (pDC) are poorly characterized. Here, we demonstrate that intestinal pDC show the characteristic plasma cell-like morphology, and recognized by antibodies against B220, Ly6c, 120G8, PDCA-1, markers typically expressed pDC. Furthermore, carry high levels of CCR9 largely absent in intestine, but not lung, liver, or secondary lymphoid organs CCR9-deficient animals. Competitive adoptive transfers reveal impaired homing to small after i.v. transfer. In...
Abstract Purpose: The prognosis for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is poor, only a minority of benefit from checkpoint immunotherapy. Talimogene laherparepvec (T-VEC), an oncolytic immunotherapy approved advanced melanoma, in combination pembrolizumab may yield enhanced antitumor activity over either agent alone. Patients Methods: This was phase Ib/III, multicenter trial testing intratumoral T-VEC combined intravenous R/M HNSCC...
PURPOSE The integration of immunotherapy in the perioperative setting muscle-invasive urothelial carcinoma (MIUC) appears promising. SAKK 06/17 investigated addition neoadjuvant durvalumab to gemcitabine/cisplatin (GC) chemotherapy followed by radical surgery and adjuvant checkpoint inhibition with durvalumab. PATIENTS AND METHODS was an investigator-initiated, open-label, single-arm phase II study including cisplatin-fit patients stage cT2-T4a cN0-1 operable MIUC. Four cycles GC combination...
MYCOBACTERIUM tuberculosis and Mycobacterium avium–intracellulare are among the common pathogens that infect patients with acquired immunodeficiency syndrome (AIDS).1 2 3 In this report, we describe a patient seropositive for human virus (HIV) whose disease clinically resembled infection M. avium–intracellulare. Numerous acid-fast rods were found in nearly all tissues examined, but cultures remained negative. Nucleic acid analyses negative tuberculosis, avium complex, leprae, electron...
Chordoma is a rare tumor of notochordal origin, currently principally treated by surgery and/or irradiation. Here, we describe the clinical outcome 3 consecutive patients with metastatic and locally advanced chordoma, different immunotherapeutic approaches. All presented fast growing tumors failure standard therapies. One was tumor-based vaccine, 2 others anti-PD1 antibodies, all impressive radiological responses. We therefore propose that chordoma an immunogenic thus translational research...
To perform a risk analysis of the cancer chemotherapy process, by comparing five different organizations. quantitatively demonstrate usefulness centralization and information technologies, to identify residual risks that may be target additional actions.A reengineering process started in 1999 was planned finished 2006. The performed after at beginning technologies integration.Two thousand two hundred beds university hospital, with medical, surgical, haematological, gynaecological, geriatric,...
CD1d-restricted T cells contribute to tumor protection, but their precise roles remain unclear. Here we show that engineered secrete granulocyte–macrophage colony-stimulating factor induce the expansion of through a mechanism involves CD1d and macrophage inflammatory protein 2 expression by CD8α – , CD11c + dendritic (DCs). The antitumor immunity stimulated vaccination with irradiated, granulocyte-macrophage factor-secreting was abrogated in CD1d- Jα281-deficient mice, revealing critical...
Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as potent radiosensitizer by arresting cells in the most radiosensitive cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine safety maximum tolerated (MTD) of Sb combination with radiation therapy (RT) temozolomide (TMZ) 17 patients newly diagnosed high-grade glioma. Patients were treated RT (60 Gy 2 fractions) combined...
Abstract Background Modern techniques of radiotherapy are supposed to decrease the incidence osteoradionecrosis mandible (ORNM). The purpose this study was compare ORNM after intensity‐modulated (IMRT) in comparison conventional 3D conformal (conventional RT). Methods We conducted a retrospective consecutive unselected patients treated single institution between 2002 and 2012. To minimize confounding effects, only with oropharyngeal carcinoma without surgery primary site were included....
To assess in a prospective, multicenter, single-arm phase I/II study the early safety and efficacy profile of single fraction urethra-sparing stereotactic body radiotherapy (SBRT) for men with localized prostate cancer.
<p>Representativeness of Study Participants</p>
Abstract Background. In oropharyngeal carcinomas, it is assumed that the effectiveness of different treatment approaches roughly equivalent, whereas functional outcome after radical radiotherapy (RT) superior to associated with primary surgery. The aim this study assess quality life (QoL) outcomes patients two strategies: surgery postoperative RT and accelerated concomitant boost or without chemotherapy. Methods. Sixty who were disease free at least 1 year oropharynx carcinoma studied. Forty...